Systemic mastocytosis;Les mastocytoses systémiques

Revue du Praticien

Volumn 55, Issue 15, 2005, Pages 1629-1636

  Fain, Olivier ^a   Stirnemann, Jerôme ^a   Lortholary, Olivier ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; CHYMOTRYPSIN; CLADRIBINE; CODEINE; CORTICOSTEROID; CORTICOTROPIN; CROMOGLYCATE DISODIUM; HALOTHANE; HYDRALAZINE; INTERFERON; IODINATED CONTRAST MEDIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MORPHINE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; POLYMYXIN B; PROTAMINE; PROTEIN TYROSINE KINASE INHIBITOR; QUININE; RESERPINE; SALICYLIC ACID; SCOPOLAMINE; STEM CELL FACTOR RECEPTOR; TUBOCURARINE CHLORIDE; UNINDEXED DRUG;

BONE; CLINICAL FEATURE; DISEASE CLASSIFICATION; GASTROINTESTINAL TRACT; GIEMSA STAIN; HUMAN; IMMUNOPHENOTYPING; LIVER; LYMPH NODE; MAST CELL; MASTOCYTOSIS; REVIEW; SKIN; SKIN MANIFESTATION; SPLEEN; SYSTEMIC MASTOCYTOSIS; TELANGIECTASIA; URTICARIA PIGMENTOSA;

ENZYME INHIBITORS; HUMANS; IMMUNOPHENOTYPING; MASTOCYTOSIS, SYSTEMIC; PROGNOSIS; PROTEIN-TYROSINE KINASES;

EID: 27244455903     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988;67:345-68.
2. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997;349:1379-85.
3. Rosenbaum RC, Frieri M, Metcalfe DD. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis. J Nucl Med 1984;25:859-64.
4. Mican JM, Di Bisceglie AM, Fong TL, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995;22:1163-70.
5. Sant GR, Theoharides TC, Letourneau R, Gelfand J. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria. Scand J Urol Nephrol 1997;31:497-500.
6. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001;57:47-55.
7. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematological disorders. Leuk Res 2001;25:553-62.
8. Kanthawatana S, Carias K, Arnaout R, Hu J, Irani AM, Schwartz LB. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999;103:1092-9.
9. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;Jul 29 [Epub ahead of print].
10. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
11. Akin C, Schwartz LB, Kitoh T, et al. Soluble stem cell factor receptor ( CD117) and IL-2 receptor alpha cahin (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow morphology. Blood 2000;96:1267-73.
12. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004;11:58-64.
13. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc 2002;77:1169-75.
14. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852-5.
15. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35-9.
16. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004;350:735-6.
17. Bouchelouche K, Nordling J, Hald T, Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001;166:1734-7.
18. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393-6.
19. Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. Bone Miner Res 2002;17:567-9.
20. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha:results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-7.
21. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249-57.
22. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-6.
23. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004;28:127-31.
24. Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis. A French multicenter study of 33 patients. Blood 2004;104:190a.
25. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99: 1741-4.
26. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;16;362:535-6.
27. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;10:3093-6.
28. Tanaka A, Konno M, Muto S, et al. A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005;105:2324-31.
29. Marrache F, Memain N, Bonte I, et al. Traitement des mastocytoses systémiques. Rev Med Interne 2003;24:594-601.